Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in pts w/ Muscle Invasive Bladder Cancer

Trial Identifier: D2615C00001
Sponsor: AstraZeneca
NCTID:: NCT02546661
Start Date: October 2016
Primary Completion Date: March 2020
Study Completion Date: September 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
ES Badalona, ES, 08003
ES Barcelona, ES, 08035
ES Barcelona, ES, 08041
ES Madrid, ES, 28040
FR Bordeaux, FR, 33075
FR CAEN, FR, 14000
FR LYON cedex 08, FR, 69373
FR MARSEILLE CEDEX 9, FR, 13273
FR Saint Herblain Cedex, FR, 44805
FR Toulouse Cedex, FR, 31100
GB Glasgow, GB, G12 0YN
GB London, GB, W1G 6AD
GB London, GB, EC1M 6BQ
GB Manchester, GB, M20 4BX
GB Southampton, GB, SO16 6YD
US, CA Los Angeles, CA, US, 90095
US, CT New Haven, CT, US, 06510
US, FL Ft Myers, FL, US, 33901
US, NY New York, NY, US, 10116
US, NY New York, NY, US, 10029
US, NY New York, NY, US, 10032
US, OH Cleveland, OH, US, 44195
US, TN Nashville, TN, US, 37203